Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

已完结 10 由拓发布于 2026/9/24 21:35:31

DOI:10.1056/nejmoa2413258
作者：Arun J Sanyal,Philip N Newsome,Iris Kliers,Laura Harms ?stergaard,Michelle T Long,Mette Skalsh?i Kj?r,Anna M G Cali,Elisabetta Bugianesi,Mary E Rinella,Michael Roden,Vlad Ratziu,
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS In this ongoing

应助信息

1天前

pinghao

7b4615aab81d11f1997834735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/9/24 21:35:31 未找到该文献，机器人已退出，请等待人工下载

2026/9/24 21:35:31 Book学术AI机器人收到请求，开始寻找文献

2026/9/24 21:35:31 已向机器人发送请求

1天前

拓发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Pair-Resolved Fe–M Dual-Atom Catalysts for Programmed PMS Activation: Mechanisms, Membrane Confinement, and Standardized Benchmarks